Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Xeris Pharmaceuticals, Inc is a biotechnology business based in the US. Xeris Pharmaceuticals shares (XERS) are listed on the NASDAQ and all prices are listed in US Dollars. Xeris Pharmaceuticals employs 172 staff and has a trailing 12-month revenue of around USD$15.1 million.
|52-week range||USD$1.42 - USD$9.69|
|50-day moving average||USD$5.1306|
|200-day moving average||USD$4.4827|
|Wall St. target price||USD$11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.113|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$15.1 million|
|Gross profit TTM||USD$1.1 million|
|Return on assets TTM||-40.62%|
|Return on equity TTM||-353.03%|
|Market capitalisation||USD$224.3 million|
TTM: trailing 12 months
There are currently 14.5 million Xeris Pharmaceuticals shares held short by investors – that's known as Xeris Pharmaceuticals's "short interest". This figure is 18% down from 17.7 million last month.
There are a few different ways that this level of interest in shorting Xeris Pharmaceuticals shares can be evaluated.
Xeris Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Xeris Pharmaceuticals shares currently shorted divided by the average quantity of Xeris Pharmaceuticals shares traded daily (recently around 1.3 million). Xeris Pharmaceuticals's SIR currently stands at 10.83. In other words for every 100,000 Xeris Pharmaceuticals shares traded daily on the market, roughly 10830 shares are currently held short.
However Xeris Pharmaceuticals's short interest can also be evaluated against the total number of Xeris Pharmaceuticals shares, or, against the total number of tradable Xeris Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xeris Pharmaceuticals's short interest could be expressed as 0.3% of the outstanding shares (for every 100,000 Xeris Pharmaceuticals shares in existence, roughly 300 shares are currently held short) or 0.3097% of the tradable shares (for every 100,000 tradable Xeris Pharmaceuticals shares, roughly 310 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Xeris Pharmaceuticals.
Find out more about how you can short Xeris Pharmaceuticals stock.
We're not expecting Xeris Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Xeris Pharmaceuticals's shares have ranged in value from as little as $1.42 up to $9.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xeris Pharmaceuticals's is 2.2639. This would suggest that Xeris Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.